加速全球创新以应对抗菌药物耐药性：介绍 CARB-X。
Accelerating global innovation to address antibacterial resistance: introducing CARB-X.
机构信息
Boston University School of Law, Boston, Massachusetts 02215, USA.
Chatham House, London SW1Y 4LE, UK.
出版信息
Nat Rev Drug Discov. 2016 Sep;15(9):589-590. doi: 10.1038/nrd.2016.155. Epub 2016 Jul 29.
PMID:27469032
Abstract
A global response to the chronic shortfall in antibiotic innovation is urgently needed to combat antimicrobial resistance. Here, we introduce CARB-X, a new global public-private partnership that will invest more than US$350 million in the next 5 years to accelerate the progression of a diverse portfolio of innovative antibacterial products into clinical trials.
摘要
为应对抗生素创新方面的长期不足，以对抗抗微生物药物耐药性，全球急需采取对策。在此，我们介绍一个新的全球公私合作伙伴关系——CARB-X，该伙伴关系将在未来 5 年内投资超过 3.5 亿美元，以加快多样化的创新型抗菌产品组合进入临床试验阶段的进程。
Zotero 插件